Cardiogen 20mg (Bioregulator Peptide)

Cardiogen

Research chemical – peptide bioregulator

Synthetic tetrapeptide cardiovascular bioregulator (research use only)

Sold as a research chemical only; not registered as a medicinal product with regulatory agencies such as the MHRA, EMA or FDA.
Some suppliers state manufacture under GMP Like or ISO Certified conditions for research chemicals; users should verify quality certifications via vendor documentation and certificates of analysis.
Use should comply with local regulations governing handling of research chemicals, peptides and biological agents in laboratory settings.

Sold as a research chemical only; not registered as a medicinal product with regulatory agencies such as the MHRA, EMA or FDA.
Some suppliers state manufacture under GMP Like or ISO Certified conditions for research chemicals; users should verify quality certifications via vendor documentation and certificates of analysis.
Use should comply with local regulations governing handling of research chemicals, peptides and biological agents in laboratory settings.

Synthetic tetrapeptide cardiovascular bioregulator (research use only)

Description

Cardiogen 20mg is a synthetic tetrapeptide bioregulator supplied as a lyophilised powder in a research-grade vial. The peptide has the amino acid sequence Ala-Glu-Asp-Arg (AEDR) and a molecular formula of C18H31N7O9 with a molecular weight of approximately 489.5 g/mol. It is classified as a cardiovascular bioregulator peptide and is investigated in preclinical settings for its potential effects on cardiac tissues, fibroblasts, cellular repair mechanisms and apoptosis regulation. Cardiogen 20mg is sold strictly for laboratory research and in vitro or in vivo experimental use, and is not approved for human or veterinary therapeutic use.

Bnefits

Synthetic tetrapeptide (AEDR: Ala-Glu-Asp-Arg) that allows highly controlled, reproducible dosing in research models.
Classified as a cardiovascular bioregulator peptide, frequently used in studies of cardiac tissue repair, cardiomyocyte metabolism and cardiovascular stress models.
Preclinical research suggests potential influence on fibroblast activity, tissue repair and scar formation, making it of interest in models of myocardial injury and remodeling.
Investigated for modulation of gene expression, apoptosis and cell proliferation, including potential effects on p53-related pathways in cardiac cells and some cancer models.
Supplied as high-purity lyophilised powder (typically ≥98–99% purity) suitable for reconstitution in standard laboratory solvents for in vitro and in vivo experiments.
Available from multiple research suppliers with supporting analytical data such as HPLC, mass spectrometry and certificates of analysis for batch verification.
Clearly labelled as a research-only product, facilitating compliance with laboratory and regulatory requirements for non-clinical use.

Indications

Intended exclusively for laboratory research use in fields such as cardiology, oncology and cell signalling.
Preclinical studies on cardiomyocyte metabolism, myocardial repair and cardiac remodeling models.
Experimental research on fibroblast function, tissue repair, scar formation and extracellular matrix remodeling.
Investigations into peptide bioregulators and their effects on gene expression, apoptosis and cellular proliferation.
In vitro and in vivo models exploring cardiovascular stress, hypertension, heart failure and ischemia–reperfusion injury.
Basic research on short regulatory peptides (bioregulators) and their potential organ-specific actions.

Composition

Active substance: Cardiogen (tetrapeptide AEDR – Ala-Glu-Asp-Arg).
Amino acid sequence: H-Ala-Glu-Asp-Arg-OH.
Molecular formula: C18H31N7O9.
Molecular weight: ~489.5 g/mol.
Typical purity: ≥98–99% (research-grade, peptide content only).
Physical form: white to off-white lyophilised powder in a sealed glass vial (commonly 3 mL vial size).
Amount of active peptide: 20 mg per vial.
Excipients: not usually specified beyond residual lyophilisation matrix; refer to individual vendor certificate of analysis for additional details.

Formulation

Presentation: 20 mg of Cardiogen tetrapeptide as lyophilised powder in a glass research vial.
Intended route in experimental settings: reconstituted for use in in vitro assays (e.g., cell culture) or in vivo animal models according to institutional protocols; not formulated for human administration.
Solubility: soluble in water and standard aqueous buffers following reconstitution; specific solvent recommendations vary by supplier.
Typical storage form: lyophilised peptide stored frozen (commonly at or below -20 °C) to preserve stability and activity.

Packaging

Primary packaging: sealed glass vial (often 3 mL) containing 20 mg of lyophilised Cardiogen peptide with a rubber stopper and crimp or screw cap.
Each vial is typically labeled with product name, peptide amount (20 mg), batch / lot number, purity, and storage conditions.
Vials are supplied in protective secondary packaging (e.g., cardboard box or protective mailer) with appropriate documentation such as certificate of analysis (CoA) and safety / handling information.
Shipped by research peptide vendors under controlled conditions appropriate for peptides, often with insulation and cold packs depending on distance and climate.

Usage

For laboratory research use only. Not for human, veterinary, diagnostic or therapeutic use.
Inspect the vial upon receipt for integrity of seal and absence of visible damage. Do not use if the vial, stopper or seal is compromised.
Allow the vial to reach room temperature before opening to minimise condensation, keeping exposure time out of cold storage as short as practical.
Reconstitute the lyophilised peptide with an appropriate sterile solvent (e.g., sterile water for injection, buffered aqueous solution or other laboratory-grade solvent) to the desired concentration, following internal laboratory SOPs and vendor guidance where provided.
Gently swirl or roll the vial to aid dissolution; avoid vigorous shaking that may cause foaming or peptide denaturation.
If required, filter the reconstituted solution through a suitable sterile low-protein-binding filter for cell culture work, in accordance with laboratory practice.
Use reconstituted solutions promptly, or aliquot into smaller volumes and store at recommended temperatures (commonly refrigerated or frozen) to minimise freeze–thaw cycles; refer to vendor-specific stability guidance.
Handle all solutions using appropriate laboratory PPE (lab coat, gloves, eye protection) and in accordance with institutional chemical safety protocols.
Dispose of any unused material and waste according to local regulations for chemical and biological laboratory waste.
Do not administer to humans or animals outside of properly approved research protocols and regulatory frameworks.

Contraindications

Not approved as a medicinal product; must not be used for self-administration, clinical treatment or any non-research purpose.
Use is contraindicated outside of controlled laboratory or preclinical research environments with appropriate safety systems in place.
Individuals with known hypersensitivity to peptides or any laboratory solvent used for reconstitution should avoid direct contact; appropriate PPE and engineering controls should be used.
Should not be handled by personnel without adequate training in laboratory safety and handling of research peptides.
Any in vivo use must be restricted to ethically approved animal studies or other regulated research contexts and conducted under institutional and regulatory oversight.

Adverse Effects

No clinical safety data are available, as Cardiogen 20mg is not approved for human use; potential adverse effects in humans are unknown.
In laboratory settings, general peptide and chemical handling hazards apply, including possible irritation or sensitisation upon skin, eye or respiratory exposure to powder or solutions.
In animal studies, any observed effects (e.g., changes in cardiovascular parameters, cellular proliferation, apoptosis markers) should be recorded as part of experimental outcomes and interpreted within the context of the specific model used.
Improper handling (e.g., aerosol generation, accidental injection or ingestion) may pose unpredictable risks and must be prevented by adherence to good laboratory practice.
All exposure incidents should be managed according to institutional emergency procedures and material safety data sheet (MSDS) recommendations where available.

Storage Conditions

Store lyophilised Cardiogen 20mg vials at or below -20 °C in a dry, dark environment, as recommended by many research peptide suppliers.
Keep vials tightly closed and in their original packaging until use, to protect from moisture and light.
After reconstitution, store aliquots at refrigerated or frozen temperatures recommended by the supplier (commonly 2–8 °C for short term or -20 °C for longer term), and minimise repeated freeze–thaw cycles.
Ensure storage in a secure laboratory area with access restricted to authorised research personnel.
Follow any additional storage and stability information provided on the vial label or in the supplier’s technical documentation.